Summary

Study on Influences of the Fixed Combination Antimalarial Drug Dihydroartemisinin Plus Piperaquine in Chromosomal Mutations in Mice

This study was carried out at National Institute of Malariology, Parasitology and Entomology and Department of Medical Biology and genetics, Hanoi Medical School, between June and October, 2006. The influences of the fixed combination antimalarial drug of 40 mg dihydroartemisinin (DHA) plus 320 mg piperaquine phosphate (PQP), with PQP produced firstly in Vietnam, in chromosomal mutations were investigated in mice at the oral dose of 360 mg/kg per day for 5 consecutive days. The results showed that:

The combination DHA-PQP increased significantly the incidences of structure disorders of chromatid and chromosome types (2.35 ± 2.94 vs 0.91 ± 0.43, P < 0.02 and 1.05 ± 1.43 vs 0.22 ± 0.51, P < 0.02, respectively) in murine bone marrow cells between the treated and control groups. It did not affect significantly in the incidences of chromosomal numeral disorders in bone marrow and testicle cells. This combination also did not affect significantly in incidences of chromosomal structure disorders in murine testicle cells (P > 0.05).

DHA-PQP was able to induce structural chromosomal mutations in murine bone marrow cells at the dose of 360 mg (40.0 mg of DHA and 360.0 mg of PQP) / kg per day for 5 consecutive days.

Keywords: fixed combination antimalarial drug, dihydroartemisinin, piperaquine phosphate, chromosome, structure disorders, number disorders, mice, bone marrow and testicle.

(Nguồn tin: )